Skip Navigation

European Heart Journal 2003 24(9):880-881; doi:10.1016/S0195-668X(02)00800-X
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Farré, J.
Right arrow Articles by Nisam, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farré, J.
Right arrow Articles by Nisam, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Response to the letter to the editor (Sharma et al.)

Jeronimo Farréa and Seah Nisamb,*

a Fundación Jiménez Diaz, Madrid, Spain
b Guidant Corporation, Brussels, Belgium

* Corresponding author. Guidant European Headquarters, Park Lane Culliganlaan 2B, Diegem 1831, Belgium (S. Nisam)

The first 10% of the full text of this article appears below.

We thank Dr. Sharma and his colleagues for their interest in our article and wish to respond to the issues they have raised.1

Regarding ß-blocker use in the MADIT study,2 Moss has shown that the ICD benefit "...remained significant after adjustment for ß-blocker use".3 The Multicenter UnSustained Tachycardia Trial (MUSTT)—with patients nearly identical in profile to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?